Next Article in Journal
In Vitro Screening of Antimicrobial and Anti-Coagulant Activities, ADME Profiling, and Molecular Docking Study of Citrus limon L. and Citrus paradisi L. Cold-Pressed Volatile Oils
Next Article in Special Issue
Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer’s Disease Risk: A Retrospective Cohort Proof-of-Concept Study
Previous Article in Journal
Drug Discovery Based on Oxygen and Nitrogen (Non-)Heterocyclic Compounds Developed @LAQV–REQUIMTE/Aveiro
Previous Article in Special Issue
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Indazole-Based Thiadiazole-Bearing Thiazolidinone Hybrid Derivatives: Theoretical and Computational Approaches to Develop Promising Anti-Alzheimer’s Candidates

1
Department of Chemistry, COMSATS University Islamabad, Islamabad 45550, Pakistan
2
Department of Chemistry, Abbottabad University of Science and Technology (AUST), Abbottabad 22500, Pakistan
3
Department of Chemistry, Hazara University, Mansehra 21120, Pakistan
4
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
5
School of Health and Biomedical Sciences, RMIT University, Melbourne 3083, Australia
6
Shangai Key Laboratory of Functional Material Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Meilong Road 130, Shanghai 200237, China
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(12), 1667; https://0-doi-org.brum.beds.ac.uk/10.3390/ph16121667
Submission received: 30 October 2023 / Revised: 18 November 2023 / Accepted: 28 November 2023 / Published: 30 November 2023

Abstract

:
A hybrid library of compounds based on indazole-based thiadiazole containing thiazolidinone moieties (117) was synthesized. The synthesized compounds were screened in vitro for their inhibition profile against targetedacetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities. All the derivatives demonstrated a varied range of inhibitory activities having IC50 values ranging from 0.86 ± 0.33 μM to 26.73 ± 0.84 μM (AChE) and 0.89 ± 0.12 μM to 27.08 ± 0.19 μM (BuChE), respectively. The results obtained were compared with standard Donepezil drugs (IC50 = 1.26 ± 0.18 μM for AChE) and (1.35 ± 0.37 μM for BuChE), respectively. Specifically, the derivatives 117, 1, 9, and 14 were found to be significantly active, with IC50 values of 0.86 ± 0.30, 0.92 ± 0.10, and 1.10 ± 0.37 μM (against AChE) and 0.89 ± 0.12, 0.98 ± 0.48 and 1.19 ± 0.42 μM (against BuChE), respectively.The structure–activity relationship (SAR) studies revealed that derivatives bearing para-CF3, ortho-OH, and para-F substitutions on the phenyl ring attached to the thiadiazole skeleton, as well as meta-Cl, -NO2, and para-chloro substitutions on the phenyl ring, having a significant effect on inhibitory potential. The synthesized scaffolds have been further characterized by using 1H-NMR, 13C-NMR, and (HR-MS) to confirm the precise structures of the synthesized compounds. Additionally, the molecular docking approach was carried out for most active compounds to explore the binding interactions established by most active compounds, with the active sites of targeted enzymes and obtained results supporting the experimental data.

Graphical Abstract

1. Introduction

Alzheimer’s disease (AD), also known as dementia, is a brain disease that affects many people. The condition is characterized by an array of symptoms that include behavioral disruptions, cognitive impairments, a variety of neuropsychiatric disorders, as well as difficulties with daily living activities due to the multifaceted neurodegenerative process. In the United States, Alzheimer’s disease (AD) is considered to be the most common form of dementia. Genetic susceptibility and environmental factors play a major role in this disease’s etiology [1]. Typically, Alzheimer’s disease (AD) affects people over 56 years of age and is generally recognized as a condition associated with aging, resulting in dementia in older individuals. A significant number of individuals aged 65 and older are affected by this condition, which accounts for approximately 10% of the population. As a result, this number increases to more than 30% among those over the age of 80 [2]. In developing nations, Alzheimer’s disease ranks second behind brain accidents, cancer, and cardiovascular diseases in terms of mortality.
AD currently affects 35 million people worldwide, and estimates suggest this number will increase to 107 million by 2050 [2]. The risk factors for cardiovascular disease, such as hypertension and high blood cholesterol levels, are strongly associated with Alzheimer’s disease [3].This process involves the degradation of neurons and the impairment of cholinergic transmission as a result. As a result of Alzheimer’s disease’s multipathogenic nature, a new drug development strategy has been developed. By targeting drugs with multiple actions, such as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), this approach is specifically beneficial for treating Alzheimer’s disease [4]. Cognitive processes, particularly memory, depend heavily on acetylcholine, a neurotransmitter. As a result of impaired cholinergic neurotransmission in the brain, Alzheimer’s disease (AD) results in cognitive dysfunction [5,6]. There is a close relationship between the enzyme BuChE and AChE [7]. A growing interest has been generated in its application for treating Alzheimer’s disease because of its potential involvement in the early phases of anticholinesterase therapies [8]. The enzymatic activity of butyrylcholinesterase (BuChE) is commonly enhanced in persons with hyperlipidemia, obesity, and hypertension. The enzymatic activity of BuChE is usually reduced in people treated with beta-blockers or who have recently suffered an acute myocardial infarction [9,10,11]. Neurotransmitter transmission can be negatively affected by inhibiting BuChE because of a decrease in enzymatic activity. There are several symptoms associated with this disorder, including high temperature, blurry vision, nausea, vomiting, dizziness, as well as death [12,13].
The blocking of BuChE, specifically, may lower the likelihood of unfavorable effects and even make it possible to achieve effectiveness while minimizing undesirable consequences [14].
In order to treat Alzheimer’s disease, pharmaceutical treatments have increasingly focused on the selective inhibition of BuChE. A combination of selective cholinesterase inhibitors and ongoing BuChE inhibitors may enhance clinical results in the future [15], as shown in Figure 1. Indazole, which belongs to the azoles group, contains carbon, nitrogen, and hydrogen. Benzpyrazole or isoindazolone are common names for this molecule. The compound consists of two nitrogen atoms and is classified as a heterocyclic organic compound. As a ten-pi-electron aromatic heterocycle, indazole exhibits similar properties to pyrazole, pyridine, and pyrrole. Numerous biological compounds and medicinal preparations rely on indazole for frameworks. Thus, chemists around the world have developed diverse approaches to synthesize these heterocycles. There are significant biological, agricultural, and industrial implications associated with indazole, an example of a heterocycle [16,17]. Previous studies have provided evidence of the diverse range of activities exhibited by indazole and its derivatives. These activities encompass anti-HIV, anti-inflammatory, anti-platelet, and 5-HT3 receptor properties, as well as anti-tumor and antagonistic effects [18,19]. Indazole binds strongly to the 5-HT1A receptor. Moreover, it has a high affinity for the I2 receptor. The pharmacological properties of this compound make the development of enhanced synthetic methodologies highly imperative [20]. Biologically active pharmaceutical compounds are commonly derived from 1,3,4-thiadiazoles. This demonstrates that pharmacologically active scaffolds can be designed and developed with many intriguing biological applications. Other thanthese activities, five-membered heterocyclic thiadiazole scaffolds have been reported to possess antioxidant properties [21,22], antidepressants [23,24], antileishmanial properties [25], glucuronidase inhibitory properties [26,27], urease inhibitory, and antifungal properties [28,29]. We developed a plan to design and synthesize indazole-containing thiadiazole derivatives as a result of the persistence of our research groups. As acetylcholinesterase inhibitors (AChE) and butyrylcholinesterase (BuChE) inhibitors, these derivatives are intended to be a novel class of compounds.

2. Results and Discussion

2.1. Chemistry

Indazole-based thiadiazole (II) was synthesized by refluxing 1H-indazole-5-carboxylic acid (I) with thiosemicarbazide in the presence of phosphorous oxychloride for four hours. The synthesized thiadiazole (II) derivative was reacted with ammonium isothiocyanate in the presence of triethylamine in ethanol and refluxed for four hours and then indazole-based thiourea derivative (III) was synthesized. Indazole-based thiadiazole-carrying thiazolidinone derivatives (IV) were synthesized by subjecting a specific compound to a reaction with thioglycolic acid in the presence of a small amount of acetic acid in an ethanol solvent for a duration of eight hours. The intermediate (IV) was subjected to reflux conditions and reacted with benzaldehyde derivatives with varying substitution patterns in response to the presence of a small amount of triethylamine (Et3N) in ethanol for a duration of 5 h. This reaction yielded a series of indazole-based thiadiazole-bearing thiazolidinone moieties (117), as discussed below in Scheme 1. The synthesized compounds were confirmed using HREIMS, 13CNMR and 1H NMR (see Supplementary Information).

2.2. In Vitro Acetylcholinesterase (AChE) Inhibitory Potential

The inhibitory potentials of the synthesized derivatives (117) based on indazole-based thiadiazole were assessed against AChE, as documented in the literature. The compounds exhibited a diverse range of acetylcholinesterase (AChE) inhibition, with values ranging from (0.86 ± 0.33 μM) to (26.73 ± 0.84 μM), in comparison to Donepezil (IC50 = 1.26 ± 0.18 μM), which served as the reference inhibitor. On the other hand, among the indazole-based thiadiazole scaffolds (117) screened, namely scaffolds 1, 9, 14, 15, and 16, these scaffolds showed a significant inhibitory effect on the acetylcholinesterase enzyme. The IC50 values for these scaffolds were determined to be 1.10 ± 0.37, 0.86 ± 0.30, 0.92 ± 0.10, 1.24 ± 0.36, and 1.20 ± 0.58 μM, respectively. It was determined that the results of the experiment were similar to the IC50 value of the ordinary drug Donepezil. As a result of the work carried out on the analogs, it was observed that certain compounds showed inhibitory effects that were moderate to relatively low, which were within the range of the reference medication, within the cohort of compounds under investigation. Despite this, it was observed that the inhibitory potentials of the compounds that were tested were reduced in comparison with the inhibitory potentials of the Donepezil reference drugs, as shown in Table 1.
Taking into account the results of the structure–activity relationship (SAR) investigation, it is evident that the activity of the synthesized compounds (117) against acetylcholinesterase (AChE) is primarily determined by the properties of the phenyl ring attached to the thiadiazole ring, including the type, position, arrangement, and nature of substitutions within the ring. The molecular structure of newly synthesized derivatives of the indazole-based 1,3,4-thiadiazole compounds, together with their respective IC50 values, are thoroughly analyzed in order to determine the unique characteristics thathave been impacted by the addition of a trifluoro group to the phenyl ring linked to the 1,3,4-thiadiazole moiety. Accordingly, it appears that the derivatives of 1,3,4-thiadiazoles, including the indazole moiety, that is, those containing a trifluoro group, are more inhibitory against acetylcholinesterase in comparison with analogous derivatives of these compounds. As a result of the presence of the trifluoro group located at the para-position of the phenyl ring, compound 9 (IC50 = 0.86 ± 0.30 μM) was determined to be the most potent analog within this series. The compound exhibited notable efficacy in comparison to the conventional Donepezil (IC50 = 1.26 ± 0.18 μM).
The -CF3 introduces electron-withdrawing properties to the phenyl ring attached to thethiadiazole skeleton, as well as its unique electronic effect that enhances lipophilicity. Based on the results of the experiment, it has been determined that it will definitely decrease the electron density and increase the biological potency of the scaffolds as well. The increased efficacy of scaffold 9 (IC50 = 0.86 ± 0.30 μM) against acetylcholinesterase might, perhaps, be related to the participation of the trifluoro group in forming hydrogen bonds with the active region of the enzyme.
There has been significant evidence that compound 14, which is characterized by the presence of ortho-hydroxy and para-fluoro substitution groups in the phenyl ring attached to the thiadiazole moiety, is highly effective against the acetylcholinesterase enzyme. Compound 14 with an IC50 value of 0.92 ± 0.10 was identified as the second most powerful compound in the series. As a result of the fluorine atoms being involved in the formation of hydrogen bonds with the enzyme active site, it is known that substitutions with fluorine can lead to the introduction of electron-withdrawing groups to the phenyl rings, thereby altering a compound’s metabolic stability, lipophilicity, and bioactivity. When compared with ortho or meta positions, the para-position is often more advantageous for steric hindrance minimization, so it is a more strategic position. Moreover, the ortho-OH substitution is basically polar in nature, which allows it to create stronger hydrogen bonds with the active sites of the enzymes, thereby increasing the pharmacokinetic properties of the scaffolds in terms of drug delivery. One of the downsides of the ortho-position is that it leads to steric hindrance as well as changes in molecular geometry, as shown in Figure 2.
Structure 14 exhibits greater efficacy against the acetylcholinesterase enzyme when compared to structures 15 and 16, as seen by its lower IC50 value of 0.92 ± 0.10. In contrast, Structure 15 exhibits an IC50 value of 1.24 ± 0.36, while Structure 16 has an IC50 value of 1.20 ± 0.58. It is likely that the observed phenomenon is due to the significant interaction between the hydroxyl (-OH) and fluorine (-F) groups on the phenyl moiety attached to the 1,3,4-thiadiazole ring. In comparison with analog 1, compound 8 displayed relatively diminished activity due to the presence of a dichloro phenyl ring. The second molecule, which has anIC50 value of 1.10 ± 0.37, has higher potential due to the inclusion of both di-chloro and -NO2 groups, which interact with the active site of the acetylcholinesterase enzyme. At meta positions, chlorine atoms can affect steric hindrance to some extent, influencing a molecule’s inhibitory potential. An aromatic ring’s electronic properties are moderately influenced by its meta position. It can influence electron density distribution within the ring, influencing overall enzymatic activities. Similarly, the nitro group is a strong electron-withdrawing group. This results in a decrease in electron density on the aromatic ring as it pulls electron density away from the ring. Consequently, the ring becomes less nucleophilic and more electrophilic due to this electron-withdrawal effect. So, the nitro group and -Cl group might increase the inhibitory potential of the synthesized compounds. When compared to compounds 1 and 8, compound 2, which contains an ortho-chloro-substituted phenyl ring connected to an indazole-thiadiazole ring, exhibited reduced inhibitory potency against acetylcholinesterase. Among the analogs 1,3,4-thiadazoles are linked to an ortho-chloro group on the phenyl ring, while analog 8 is linked to an ortho-alkyl group. The IC50 value of compound 2 was found to be 3.11 ± 0.59, indicating its inhibitory efficacy. Conversely, compound 7, which contains an electron-withdrawing -NO2 in the para-position, significantly showed a similar potential against both AChE and BuChE, as shown in Figure 2.
Compound 10 (IC50 = 24.68 ± 0.12), compound 11 (IC50 = 26.73 ± 0.84), compound 12 (IC50= 25.12 ± 0.18), and compound 17 (IC50 = 22.30 ± 1.00) demonstrate comparable inhibitory properties due to the presence of a bromo group on the phenyl ring connected to the 1,3,4-thiadiazole moiety in each of these compounds. Compound 17, characterized by the presence of a nitro group in the meta-position on the phenyl ring attached to the 1,3,4-thiadiazole ring, has comparatively superior effectiveness against the acetylcholinesterase enzyme when compared to 10, 11, and 12 scaffolds but shows less effectiveness as compared to the standard drugs. The observed augmentation in activity can be attributed to the electron-withdrawing characteristics of the -NO2 moiety. Compounds 3, 4, 5, and 6, which possess a methoxy group and a methyl group at the ortho, meta, and para-positions, respectively, have a diminished inhibitory capacity (IC50 values of 8.26 ± 0.40, 8.60 ± 1.05, 10.43 ± 0.98, and 12.73 ± 0.33) in comparison to the reference medication Donepezil. In a similar vein, it was demonstrated that compound 13, which features a naphthalene ring, exhibited no discernable activity, as shown in Table 1.

2.3. In Vitro Butyrylcholinesterase (BuChE) Inhibitory Potential

In this study, thiadiazole derivatives of indazole (117) were evaluated against butyrylcholinesterase (BuChE) according to reported methodologies. The compounds demonstrated a wide spectrum of butyrylcholinesterase (BuChE) inhibition, as seen by their IC50 values, which varied from 0.89 ± 0.12 μM to 27.08 ± 0.19 μM. The range of values obtained for the inhibitor under investigation was compared to those of the standard inhibitor, Donepezil, which exhibited an IC50 value of 1.35 ± 0.37 μM. Among the seventeen scaffolds that were subjected to testing, it was observed that five specific scaffolds (scaffolds 1, 9, 14, 15, and 16) demonstrated noteworthy inhibitory effects on the enzyme butyrylcholinesterase (BuChE). The IC50 values for these scaffolds were determined to be 1.19 ± 0.42, 0.89 ± 0.12, 0.98 ± 0.48, 1.27 ± 0.40, and 1.20 ± 0.47 micromolar (μM), respectively. According to the results, the IC50 value for the reference drug Donepezil is similar to the observed values. The remaining twelve compounds were somewhat equivalent, and some compounds showed lower inhibitory potential as compared to standard Donepezil. There were, however, some analogs with moderate inhibitory potential. Through a thorough analysis of the molecular structure of newly synthesized derivatives of indazole-based 1,3,4-thiadiazole compounds and their respective IC50 values, it was observed that the incorporation of a trifluoro group onto the phenyl group attached to the 1,3,4-thiadiazole ring led to a significant improvement in their intrinsic properties. Thus, indazole-based derivatives, including 1,3,4-thiadiazole, specifically with trifluoro, para-fluoro, di-chloro, and nitro substituents, significantly suppress butyrylcholinesterase (BuChE) as compared to analogous compounds. These groups are important because they have good binding interactions with enzyme-active domains. Compound 9, with an IC50 value of 0.89 ± 0.12 μM, was identified as the most efficacious derivative in this series owing to the inclusion of a para-positioned tri-fluoro group adjacent to the phenyl ring. The molecule has significant effectiveness similar to the well-established standard Donepezil, as evidenced by its reported IC50 value of 1.35 ± 0.37 μM. The enhanced efficacy of alternative scaffolds 1 (IC50 = 1.19 ± 0.42 μM), 14 (IC50 = 1.10 ± 0.37 μM), 15 (IC50 = 1.27 ± 0.40 μM), and 16 (IC50 = 1.20 ± 0.47 μM) against butyrylcholinesterase (BuChE) may potentially be attributed to the presence of fluoro, di-chloro, nitro, and hydroxy groups, which have the ability to establish hydrogen bonds with the active site of the targeted enzyme, as shown in Table 1.

2.4. Docking Study of the Synthesized Compounds (117)

The acetylcholinesterase and butyrylcholinesterase inhibitions of the synthesized derivatives of indazole-based thiadiazole-bearing thiazolidinone derivatives (117) are shown in Table 1. The IC50 values of indazole-based thiadiazole derivatives indicate that the inhibition of acetylcholinesterase is greatly affected by the specific positions, types, and nature of substituted functional groups on the aromatic ring of the core structure. A molecular docking study was conducted using the docking tools Auto Dock Vina, Discovery Studio Visualizer (DSV), and Pymol, keeping the co-ordinate configuration of X = 18.221339, Y= 7.684984, Z = 49.559016 for AchE and co-ordinate configuration of X = 0.105784, Y = −2.213477, Z = −22.937114 for BuChE to obtain insight into the observed enzymatic inhibition of the synthesized derivatives and to assess the influence of different parameters, such as the type, number, and position of substituted functional groups, on cholinesterase (ChE) inhibition. The objective of this investigation was to determine the specific ways in which the synthesized compounds interacted with the active site residues of AChE and BuChE. The significance of the ortho, meta, and para locations of the substituted functional group on the inhibition of acetylcholinesterase, as quantified by IC50 values, is noteworthy. The aforementioned sites have a significant impact on both the number and characteristics of the intermolecular interactions that take place between the substituted functional group and the active amino acids present in acetylcholinesterase. Compounds 1, 9, 14, and 16 have structural differences in the positioning of the substituted trifluoro, fluorine, chlorine, and hydroxy groups at the ortho, para, and meta positions, correspondingly. The experimental results suggest that compound 9 has a higher level of inhibition of acetylcholinesterase in comparison to compounds 1, 14, and 16. The observed result aligns with a greater frequency of interactions taking place between the trifluoro group located at the para-position of compound 9, as opposed to compounds 1 and 14. Electronegative elements, including fluorine (-F), chlorine (-Cl), and nitrogen (-N) atoms, are known to have strong interactions with various active sites of amino acids, as shown in Figure 3, Figure 4, Figure 5, Figure 6, Figure 7 and Figure 8, with their respective receptor, types of interaction, and their docking score, as shown in Table 2.

3. Materials and Method

3.1. General Information

A large number of chemical reagents and chemicals were purchased from Sigma-Aldrich and Alfa Aesar for the purposes of this study. On the basis of an Advance Bruker spectrometer, NMR spectra of 1H and 13C in DMSO-d6 were recorded at 600 MHz and 150 MHz, respectively. An LCMS-IT-TOF system from Schimadzu Japan (Kyoto, Japan) was used to obtain mass spectra for the analysis of the samples. The melting point of the sample was determined by using the B-chi melting point-560 apparatus. A silica gel GF254 coating was applied to aluminum plates in order to monitor the progress of the reaction.

3.2. General Procedure for the Synthesis of Indazole-Based Thiadiazole-Bearing Thiazolidinone Scaffold

In the first step, indazole-based thiadiazole (I) was synthesized by refluxing 1H-indazole-5-carboxylic acid (1 mmol) with thiosemicarbazide (1mmol) in the presence of phosphorous oxychloride (30 mL) for four hours. The synthesized thiadiazole (II) (1 mmol) was reacted further with ammonium isothiocyanate (1 mmol) in the presence of triethylamine (two to three drops) in ethanol and refluxed for four hours, and indazole-based thiourea derivative (III) was synthesized, which was further reacted with thioglycolic acid (1 mmol) in the presence of few drops of acetic acid in ethanol for eight hours.Indazole-derived thiadiazole-based thiazolidinone derivative (IV) was synthesized. The intermediate (IV) (1 mmol) was further reacted under reflux with variously substituted benzaldehyde (1 mmol) in the presence of a few drops of Et3N in ethanol for 5 h and with indazole-based thiadiazole-bearing thiazolidinone derivatives (117). The reaction was monitored through TLC.

3.3. Spectral Analysis

3.3.1. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3,4-Dichloro-5-Nitrobenzylidene)Thiazolidin-4-One (1)

Yield 69%, off-white solid, M.P 228–229 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.27 (s, 1H, N-H), 11.86 (s, 1H, N-H), 8.81 (d, J= 7.0 Hz, 1H, HAr), 8.54 (s, 1H, HAr), 8.37 (s, 1H, HAr), 8.22 (d, J= 6.9 Hz, 1H, HAr), 7.93 (s, 1H, HAr), 7.84 (s, 1H, Halkene), 7.68 (s, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 177.6, 174.2, 168.6, 168.3, 162.8, 160.1, 157.3, 152.7, 147.1, 147.0, 142.9, 141.7, 138.4, 136.1, 136.0, 131.3, 130.9, 125.2, 120.4; HREI-MS: m/z calcld for C19H9N7Cl2O3S2, [M]+ 518.4344 Found 518. 4332.

3.3.2. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-2-Chlorobenzylidene)Thiazolidin-4-One (2)

Yield 73%, pale-yellow solid, M.P 213–214 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.29 (s, 1H, N-H), 11.92 (s, 1H, N-H), 8.61 (d, J = 7.3 Hz, 1H, HAr), 8.44 (s, 1H, HAr), 8.39 (s, 1H, HAr), 8.31 (d, J= 6.4 Hz, 1H, HAr), 8.11 (dd, J = 6.7, 1.3 Hz, 1H, HAr), 7.89 (s, 1H, Halkene), 7.74 (dd, J = 7.0, 1.9 Hz, 1H, HAr), 7.68 (t, J = 6.9 Hz, 2H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 173.4, 171.6, 168.5, 166.4, 159.4, 156.7, 154.3, 151.2, 150.3, 148.4, 145.3, 142.1, 140.3, 136.4, 132.9, 130.6, 129.7, 126.1, 121.5; HREI-MS: m/z calcld for C19H11ClN6OS2, [M]+ 438.6539 Found 438. 6526.

3.3.3. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-2,4-Dimethylbenzylidene)Thiazolidin-4-One (3)

Yield 57%, off-white solid, M.P 205–206 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.37 (s, 1H, N-H), 11.91 (s, 1H, N-H), 8.73 (d, J = 7.1 Hz, 1H, HAr), 8.67 (s, 1H, HAr), 8.43 (s, 1H, HAr), 8.39 (d, J= 6.3 Hz, 1H, HAr), 8.12 (d, J = 6.8 Hz, 1H, HAr), 7.90 (s, 1H, Halkene), 7.78 (s, 1H, HAr), 7.69 (d, J = 6.4 Hz, 1H, HAr), 2.34 (s, 6H, CH3); 13C-NMR (150 MHz, DMSO-d6): δ 178.3, 176.2, 169.7, 162.4, 159.4, 154.2, 152.6, 150.7, 150.1, 144.5, 141.8, 139.5, 139.0, 134.7, 131.6, 130.4, 129.4, 121.6, 118.2, 32.7, 32.3; HREI-MS: m/z calcld for C21H16N6OS2, [M]+ 442.4087 Found 442.4078.

3.3.4. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3,5-Dimethylbenzylidene)Thiazolidin-4-One (4)

Yield 64%, off-white solid, M.P 208–209 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.16 (s, 1H, N-H), 11.87 (s, 1H, N-H), 8.87 (d, J = 7.1 Hz, 1H, HAr), 8.45 (s, 1H, HAr), 8.31 (s, 1H, HAr), 8.23 (d, J= 7.0 Hz, 1H, HAr), 7.86 (s, 1H, HAr), 7.81 (s, 1H, Halkene), 7.61 (s, 1H, HAr), 7.51 (s, 1H, HAr), 2.47 (s, 6H, CH3); 13C-NMR (150 MHz, DMSO-d6): δ 175.6, 173.3, 169.6, 168.2, 163.8, 159.1, 157.3, 153.8, 148.1, 145.5, 141.9, 140.8, 139.7, 137.4, 136.8, 132.3, 131.9, 127.3, 119.3, 20.5, 20.2; HREI-MS: m/z calcld for C21H16N6OS2, [M]+ 432.4134 Found 432. 4125.

3.3.5. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-Methoxybenzylidene)Thiazolidin-4-One (5)

Yield 78%, off-white solid, M.P 211–212 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.37 (s, 1H, N-H), 11.99 (s, 1H, N-H), 8.76 (d, J= 7.3 Hz, 1H, HAr), 8.64 (d, J = 6.3 Hz, 1H, HAr), 8.55 (s, 1H, HAr), 8.49 (s, 1H, HAr), 7.91 (d, J= 6.5 Hz, 2H, HAr), 7.62 (s, 1H, Halkene), 7.57 (d, J= 6.4 Hz, 2H, HAr), 3.51 (s, 3H, -OCH3); 13C-NMR (150 MHz, DMSO-d6): δ 180.4, 176.3, 167.2, 164.4, 163.5, 161.5, 161.4, 158.6, 156.9, 153.4, 152.1, 146.1, 143.6, 141.9, 141.4, 138.4, 134.9, 127.5, 123.6, 55.8; HREI-MS: m/z calcld for C20H14N6O2S2, [M]+ 434.2760 Found 434.2749.

3.3.6. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3-Methoxybenzylidene)Thiazolidin-4-One (6)

Yield 70%, off-white solid, M.P 218–219 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.37 (s, 1H, N-H), 11.90 (s, 1H, N-H), 8.78 (d, J= 7.0 Hz, 1H, HAr), 8.63 (s, 1H, HAr), 8.51 (s, 1H, HAr), 8.34 (d, J= 6.8 Hz, 1H, HAr), 7.81 (dd, J = 7.0, 2.2 Hz, 1H, HAr), 7.61 (s, 1H, Halkene), 7.63 (t, J= 7.0 Hz, 1H, HAr), 7.53 (s, 1H, HAr), 7.49 (dd, J= 7.1, 2.3 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 177.8, 175.1, 164.2, 161.8, 157.2, 156.2, 153.1, 152.0, 150.7, 149.4, 148.1, 144.7, 143.8, 139.1, 137.2, 134.0, 127.6, 126.3, 121.8, 54.8; HREI-MS: m/z calcld for C20H14N6O2S2, [M]+ 434.7276 Found 434.7261.

3.3.7. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-Nitrobenzylidene)Thiazolidin-4-One (7)

Yield 81%, light-yellow solid, M.P 222–223 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.33 (s, 1H, N-H), 11.93 (s, 1H, N-H), 8.72 (d, J = 7.0 Hz, 1H, HAr), 8.64 (d, J = 7.0 Hz, 1H, HAr), 8.57 (s, 1H, HAr), 8.52 (s, 1H, HAr), 7.81 (d, J = 6.0 Hz, 2H, HAr), 7.61 (s, 1H, Halkene), 7.53 (d, J = 6.8 Hz, 2H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 178.5, 171.8, 163.8, 162.7, 160.4, 160.2, 153.6, 153.6, 151.9, 150.7, 149.7, 147.7, 144.6, 143.7, 139.6, 136.7, 131.7, 121.8, 119.9; HREI-MS: m/z calcld for C19H11N7O3S2, [M]+ 449.1756 Found 449.1741.

3.3.8. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3,4-Dichlorobenzylidene)Thiazolidin-4-one (8)

Yield 62%, yellow solid, M.P 218–219 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.31 (s, 1H, N-H), 11.89 (s, 1H, N-H), 8.71 (d, J= 7.0 Hz, 1H, HAr), 8.59 (s, 1H, HAr), 8.43 (s, 1H, HAr), 8.39 (d, J = 6.7 Hz, 1H, HAr), 7.87 (d, J= 6.8 Hz, 1H, HAr), 7.81 (s, 1H, Halkene), 7.70 (s, 1H, HAr), 7.63 (d, J= 6.8 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 175.7, 173.8, 168.1, 161.7, 159.4, 156.2, 154.1, 152.7, 151.8, 146.2, 144.1, 140.1, 140.0, 137.6, 134.6, 133.2, 131.1, 127.4, 122.8; HREI-MS: m/z calcld for C19H10Cl2N6OS2, [M]+ 473.4312 Found 473.4303.

3.3.9. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-(Trifluoromethyl)Benzylidene)Thiazolidin-4-One (9)

Yield 62%, white solid, M.P 226–227 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.42 (s, 1H, N-H), 11.83 (s, 1H, N-H), 8.75 (d, J = 6.5 Hz, 1H, HAr), 8.56 (s, 1H, HAr), 8.49 (s, 1H, HAr), 8.24 (d, J = 7.0 Hz, 1H, HAr), 7.92 (d, J = 7.0 Hz, 2H, HAr), 7.81 (s, 1H, Halkene), 7.62 (d, J = 6.5 Hz, 2H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 171.3, 169.7, 166.1, 164.0, 161.4, 156.1, 155.9, 151.8, 150.9, 150.2, 146.2, 141.7, 147.6, 141.6, 134.5, 132.0, 130.7, 125.6, 122.4, 119.1; HREI-MS: m/z calcld for C20H11F3N6OS2, [M]+ 472.2731 Found 472.2718.

3.3.10. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-Bromobenzylidene)Thiazolidin-4-One (10)

Yield 78%, off-white solid, M.P 231–232 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.28 (s, 1H, N-H), 11.72 (s, 1H, N-H), 8.63 (d, J = 7.0 Hz, 1H, HAr), 8.45 (s, 1H, HAr), 8.39 (s, 1H, HAr), 8.12 (d, J = 7.2 Hz, 1H, HAr), 7.89 (d, J = 7.3 Hz, 2H, HAr), 7.74 (s, 1H, Halkene), 7.58 (d, J = 6.8 Hz, 2H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 177.9, 174.9, 169.4, 166.8, 160.5, 157.3, 156.6, 154.8, 150.3, 147.6, 143.1, 142.8, 140.6, 140.2, 136.2, 133.7, 133.4, 128.5, 117.6; HREI-MS: m/z calcld for C19H11BrN6OS2, [M]+ 483.2341 Found 483.2330.

3.3.11. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3-Bromobenzylidene)Thiazolidin-4-One (11)

Yield 60%, off-white solid, M.P 226–227 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.32 (s, 1H, N-H), 11.87 (s, 1H, N-H), 8.79 (d, J = 6.3 Hz, 1H, HAr), 8.63 (s, 1H, HAr), 8.52 (s, 1H, HAr), 8.29 (d, J = 7.1 Hz, 1H, HAr), 7.86 (dd, J = 6.8, 2.1 Hz, 1H, HAr), 7.74 (s, 1H, Halkene), 7.62 (t, J = 7.3 Hz, 1H, HAr), 7.51 (s, 1H, HAr), 7.43 (dd, J = 7.1, 2.3 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 179.8, 177.2, 161.2, 160.4, 156.7, 153.1, 150.1, 150.0, 149.6, 141.4, 139.3, 134.1, 130.4, 130.1, 127.5, 124.8, 121.6, 118.5, 112.1; HREI-MS: m/z calcld for C19H11BrN6OS2, [M]+ 483.9229 Found 483.9217.

3.3.12. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3-Bromo-5-Methylbenzylidene)Thiazolidin-4-One (12)

Yield 65%, off-white solid, M.P 229–230 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.23 (s, 1H, N-H), 11.92 (s, 1H, N-H), 8.58 (d, J = 6.2 Hz, 1H, HAr), 8.43 (s, 1H, HAr), 8.39 (s, 1H, HAr), 8.26 (d, J = 7.2 Hz, 1H, HAr), 7.93 (s, 1H, HAr), 7.84 (s, 1H, Halkene), 7.64 (s, 1H, HAr), 7.52 (s, 1H, HAr), 2.34 (s, 3H, CH3); 13C-NMR (150 MHz, DMSO-d6): δ 174.1, 170.0, 167.2, 164.8, 159.1, 153.2, 150.6, 150.4, 149.9, 144.7, 141.1, 140.0, 139.1, 137.0, 133.9, 131.3, 130.5, 128.4, 118.6, 30.5; HREI-MS: m/z calcld for C20H13BrN6OS2, [M]+ 497.4089 Found 497. 4081.

3.3.13. (2Z,5E)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-(Naphthalen-1-Ylmethylene)Thiazolidin-4-One (13)

Yield 63%, white solid, M.P 221–222 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.27 (s, 1H, N-H), 12.03 (s, 1H, N-H), 8.41 (d, J = 7.2 Hz, 1H, HAr), 8.54 (s, 1H, HAr), 8.51 (s, 1H, HAr), 8.43 (dd, J = 6.5 Hz, 1H, HAr), 8.23 (dd, J= 6.9, 1.3 Hz, 1H, HAr), 8.18 (d, J= 6.7 Hz, 1H, HAr), 8.13 (dd, J= 6.7, 1.4 Hz, 1H, HAr), 8.01 (t, J = 6.7 Hz, 1H, HAr), 7.89 (s, 1H, Halkene), 7.64 (dd, J = 6.5, 1.8 Hz, 1H, HAr), 7.59 (t, J = 7.1 Hz, 1H, HAr), 7.59 (t, J= 7.1 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 177.6, 176.3, 164.8, 163.9, 159.1, 158.4, 155.1, 153.8, 152.3, 149.4, 147.8, 144.7, 140.4, 138.5, 136.8, 134.4, 132.9, 127.5, 125.8, 123.8, 123.2, 119.2, 115.7; HREI-MS: m/z calcld for C23H14N6OS2, [M]+ 454.2150 Found 454. 2143.

3.3.14. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-Fluoro-2-Hydroxybenzylidene)Thiazolidin-4-One (14)

Yield 69%, light-yellow solid, M.P 218–219 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.13 (s, 1H, N-H), 11.31 (s, 1H, N-H), 10.34 (s, 1H, OH), 8.51 (d, J = 6.8 Hz, 1H, HAr), 8.39 (s, 1H, HAr), 8.37 (s, 1H, HAr), 8.19 (d, J = 7.0 Hz, 1H, HAr), 7.89 (d, J= 7.2 Hz, 1H, HAr), 7.81 (s, 1H, Halkene), 7.60 (s, 1H, HAr), 7.51 (d, J = 6.9 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 172.1, 169.8, 164.7, 163.2, 157.2, 154.1, 153.6, 151.4, 150.5, 148.2, 146.1, 144.1, 140.1, 140.0, 139.9, 136.3, 133.5, 122.9, 120.1; HREI-MS: m/z calcld for C19H11FN6O2S2, [M]+ 438.4345 Found 528.4332.

3.3.15. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-2-Fluorobenzylidene)Thiazolidin-4-One (15)

Yield 65%, off-white solid, M.P 216–218 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.21 (s, 1H, N-H), 11.96 (s, 1H, N-H), 8.63 (d, J= 7.1 Hz, 1H, HAr), 8.48 (s, 1H, HAr), 8.44 (s, 1H, HAr), 8.36 (d, J = 6.9 Hz, 1H, HAr), 8.02 (dd, J = 6.8, 1.2 Hz, 1H, HAr), 7.91 (s, 1H, Halkene), 7.83 (dd, J= 7.3, 2.0 Hz, 1H, HAr), 7.64 (t, J= 6.5 Hz, 2H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 175.4, 173.1, 166.5, 164.8, 159.2, 158.7, 159.3, 153.1, 152.3, 150.7, 147.0, 146.1, 143.7, 138.9, 135.8, 131.4, 131.1, 121.4, 120.3; HREI-MS: m/z calcld for C19H11FN6OS2, [M]+ 422.4531 Found 422. 4524.

3.3.16. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-3-Fluorobenzylidene)Thiazolidin-4-One (16)

Yield 83%, off-white solid, M.P 221–222 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.19 (s, 1H, N-H), 11.93 (s, 1H, N-H), 8.71 (d, J= 7.0 Hz, 1H, HAr), 8.53 (s, 1H, HAr), 8.50 (s, 1H, HAr), 8.39 (d, J = 6.7 Hz, 1H, HAr), 7.92 (dd, J = 6.9, 1.3 Hz, 1H, HAr), 7.81 (s, 1H, Halkene), 7.79 (t, J = 7.1 Hz, 1H, HAr), 7.67 (s, 1H, HAr), 7.49 (dd, J= 7.0, 2.1 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 178.1, 176.7, 165.2, 163.4, 158.7, 157.1, 154.1, 150.4, 150.3, 145.7, 141.0, 140.7, 140.4, 139.1, 139.0, 135.4, 131.5, 123.4, 121.8; HREI-MS: m/z calcld for C19H11FN6OS2, [M]+ 422.6123 Found 422.6111.

3.3.17. (Z)-2-((5-(1H-Indazol-5-yl)-1,3,4-Thiadiazol-2-yl)Imino)-5-((E)-4-Bromo-3-Nitrobenzylidene)Thiazolidin-4-One (17)

Yield 74%, yellow solid, M.P 234–235 °C, 1H-NMR (600 MHz, DMSO-d6): δ 12.25 (s, 1H, N-H), 11.95 (s, 1H, N-H), 8.65 (d, J = 6.8 Hz, 1H, HAr), 8.34 (s, 1H, HAr), 8.32 (s, 1H, HAr), 8.09 (d, J = 6.9 Hz, 1H, HAr), 7.99 (d, J = 6.7 Hz, 1H, HAr), 7.83 (s, 1H, Halkene), 7.63 (s, 1H, HAr), 7.51 (d, J = 6.0 Hz, 1H, HAr); 13C-NMR (150 MHz, DMSO-d6): δ 179.2, 175.1, 163.4, 162.9, 159.2, 158.9, 155.2, 151.1, 150.2, 148.7, 143.2, 142.1, 141.2, 141.0, 139.1, 132.2, 130.5, 128.7, 122.4; HREI-MS: m/z calcld for C19H10BrN7O3S2, [M]+ 528.4107 Found 528.4092.

3.4. Inhibition Assay of Anticholinesterase/Butyrylcholinesterase Assay

A spectrophotometric analysis was conducted by Ellman et al. to determine the inhibition of ChEs (AChE and BuChE). The substrates ATCh and BTCh were employed for the purpose of inhibiting the enzymes AChE and BuChE (human sigma 9000-81-1 and 9001-08-5, respectively). An incubation of 15 min was performed at room temperature with 140 L of sodium phosphate buffer (pH 8.0), 20 L of AChE/BuChE solution, and 20 L of the test sample. AChE/BuChE solutions containing DTNB were introduced into the 10 L solution to initiate the reaction. An enzymatic inhibition by AChE and BuChE was not detected during the 15min hydrolysis of DTNB with thiocholine, while ATCh or BTCh acted as catalysts. A percentage of inhibition was calculated using the ratio of enzyme activity in the presence of the test sample (E), minus enzyme activity without the test sample (S), expressed as E–S/E100. Each substance’s inhibition of substrate hydrolysis by ChE was quantified using its IC50 value (g/mL) or M. Compounds with the same IC50 values are calculated using the same standardized plot. Calculating the IC50 value involves equating Y to 50 and then using the x-axis to determine the concentration at which 50% of the inhibitory effect is achieved [30].

3.5. Docking Studies

We investigated the binding mechanisms among the indole-based thiadiazole-bearing thiazolidinone derivatives (117) and the active residues of acetylcholinesterase and butyrylcholinesterase using Autodock. The initial docked geometry of acetylcholinesterase and butyrylcholinesterase can be found on the RCSB data bank website (PDB code 4EY7). Co-crystallized structures of receptor–ligand complexes allow for the identification of the active site of acetylcholinesterase and butyrylcholinesterase. A successful replication of the re-docking process for Donepezil into the active site has been achieved, resulting in a root mean square deviation value of 0.63. This was achieved using the Merck molecular force field 94 at level 44. The PDB files that were created from the MMFF94 have then been used to optimize the molecule geometry of the derivatives of the compounds. To determine the binding locations of the original ligand and its synthesized derivatives, a Lamarckian genetic algorithm was used with a total of 500 runs [31,32,33,34].

4. Conclusions

In this study, we established a facile protocol for the synthesis of indazole-derived thiadiazole-based thiazolidinone hybrid derivatives (117) by cyclization of indazolethiadiazole-based thiourea substrate with thioglycolic acid, followed by a reaction with benzimidazole. The reaction features, such as high efficiency, mild reaction conditions, simple operation, and short reaction time, make it an attractive alternative for the synthesis of indazole-based 1,3,4-thiadiazole. In addition, all the newly synthesized derivatives were characterized spectroscopically through 1HNMR, 13CNMR, and HRMS. The synthesized motifs were evaluated in vitro for their acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activity. All the newly synthesized analogs showed good to moderate inhibitory potentials, ranging from 0.86 ± 0.30 μM to 26.73 ± 0.84 μM and 0.89 ± 0.12 to 27.08 ± 0.12 μM against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), respectively. Among the series, compounds 9 (IC50 = 0.86 ± 0.30 ΜmandIC50 = 0.89 ± 0.12 μM), 14 (IC50 = 0.92 ± 0.10 μM and IC50 = 0.98 ± 0.48 μM), 1 (IC50 = 1.10 ± 0.37 μMandIC50 = 1.19 ± 0.42 μM), and 16 (IC50 = 1.20 ± 0.58 μM and IC50 = 1.20 ± 0.12 μM) having trifluoro, -F, -OH, di-Cl, and -NO2 substitution at the N-phenyl ring of the indazole-based thiadiazole ring were found to be highly potent inhibitors against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes, respectively. The binding interactions of most active analogs with the active site of enzymes were recognized with the help of molecular docking studies.

Supplementary Materials

The following supporting information can be downloaded at: https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/ph16121667/s1, Figure S1: 13C NMR for the compound 3 (Z)-2-((5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl)imino)-5-((E)-2,4-dimethylbenzylidene)thiazolidin-4-one. Figure S2: 1H NMR for the compound 5 (Z)-2-((5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl)imino)-5-((E)-4-methoxybenzylidene)thiazolidin-4-one. Figure S3: 13C NMR for the compound 12 (Z)-2-((5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl)imino)-5-((E)-3-bromo-5-methylbenzylidene)thiazolidin-4-one. Figure S4: 1H NMR for the compound 13 (2Z,5E)-2-((5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl)imino)-5-(naphthalen-1-ylmethylene)thiazolidin-4-one. Figure S5: 13C NMR for the compound 13 (2Z,5E)-2-((5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl)imino)-5-(naphthalen-1-ylmethylene)thiazolidin-4-one.

Author Contributions

Methodology, R.H.; formal analysis, N.A. and H.A.G.; resources, H.W.D.; writing—original draft preparation, Y.K.; writing—review and editing, W.R.; visualization, S.K.; supervision, A.M. and U.G.; funding acquisition, M.W.A. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by Researchers Supporting Project number (RSPD2023R760), King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and Supplementary Material.

Acknowledgments

The authors extend their appreciation to the Researchers Supporting Project number (RSPD2023R760), King Saud University, Riyadh, Saudi Arabia, for funding this work.

Conflicts of Interest

The authors declare that they have no known competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.

References

  1. Chochinov, H.M.; Wilson, K.G.; Enns, M.; Lander, S. Are you depressed? Screening for depression in the terminally ill. Am. J. Psychiatry 1997, 154, 674–676. [Google Scholar] [PubMed]
  2. Berchtold, N.C.; Cotman, C.W. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. Neurobiol. Aging 1998, 19, 173–189. [Google Scholar] [CrossRef] [PubMed]
  3. De la Torre, J.C. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 2002, 33, 1152–1162. [Google Scholar] [CrossRef] [PubMed]
  4. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347–372. [Google Scholar] [CrossRef] [PubMed]
  5. Giacobini, E. Cholinesterases: New roles in brain function and in Alzheimer’s disease. Neurochem. Res. 2003, 28, 515–522. [Google Scholar] [CrossRef] [PubMed]
  6. Holzgrabe, U.; Kapková, P.; Alptüzün, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets 2007, 11, 161–179. [Google Scholar] [CrossRef] [PubMed]
  7. Whittaker, V.P. How the cholinesterases got their modern names. Chem.-Biol. Interact. 2010, 187, 23–26. [Google Scholar] [CrossRef] [PubMed]
  8. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 4, 131–138. [Google Scholar] [CrossRef]
  9. Alcantara, V.M.; Chautard-Freire-Maia, E.A.; Scartezini, M.; Cerci, M.S.J.; Braun-Prado, K.; Picheth, G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand. J. Clin. Lab. Investig. 2002, 62, 399–404. [Google Scholar] [CrossRef]
  10. Magarian, E.O.; Dietz, A.J. Correlation of cholinesterase with serum lipids and lipoproteins. J. Clin. Pharmacol. 1987, 27, 819–820. [Google Scholar] [CrossRef]
  11. Berry, W.T.C.; Cowin, P.J.; Davies, D.R. A relationship between body fat and plasma pseudo-cholinesterase. Br. J. Nutr. 1954, 8, 79–82. [Google Scholar] [CrossRef] [PubMed]
  12. Pardío, V.T.; Ibarra, N.; Rodríguez, M.A.; Waliszewski, K.N. Use of cholinesterase activity in monitoring organophosphate pesticide exposure of cattle produced in tropical areas. J. Agric. Food Chem. 2001, 49, 6057–6062. [Google Scholar] [CrossRef] [PubMed]
  13. Wang, J.; Timchalk, C.; Lin, Y. Carbon nanotube-based electrochemical sensor for assay of salivary cholinesterase enzyme activity: An exposure biomarker of organophosphate pesticides and nerve agents. Environ. Sci. Technol. 2008, 42, 2688–2693. [Google Scholar] [CrossRef] [PubMed]
  14. Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.S.; Mamczarz, J.; Holloway, H.W.; Giordano, T.; et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA 2005, 102, 17213–17218. [Google Scholar] [CrossRef]
  15. Woo, Y.J.; Lee, B.H.; Yeun, G.H.; Kim, H.J.; Won, M.H.; Kim, S.H.; Lee, B.H.; Park, J.H. Selective butyrylcholinesterase inhibitors using polyphenol-polyphenol hybrid molecules. Bull. Korean Chem. Soc. 2011, 32, 2593–2598. [Google Scholar] [CrossRef]
  16. Mills, A.D.; Nazer, M.Z.; Makhluf, J.H.; Kurth, M.J. N,N-Bond-Forming Heterocyclization: Synthesis of 3-Alkoxy-2H-indazoles. J. Org. Chem. 2006, 71, 2687–2689. [Google Scholar] [CrossRef]
  17. Zhang, T.; Bao, W. Synthesis of 1 H-indazoles and 1 H-pyrazoles via FeBr3/O2 mediated intramolecular C–H amination. J. Org. Chem. 2013, 78, 1317–1322. [Google Scholar] [CrossRef]
  18. Li, P.; Wu, C.; Zhao, J.; Rogness, D.C.; Shi, F. Synthesis of substituted 1 H-indazoles from arynes and hydrazones. J. Org. Chem. 2012, 77, 3149–3158. [Google Scholar] [CrossRef]
  19. Spiteri, C.; Keeling, S.; Moses, J.E. New synthesis of 1-substituted-1 H-indazoles via 1, 3-dipolar cycloaddition of in situ generated nitrile imines and benzyne. Org. Lett. 2010, 12, 3368–3371. [Google Scholar] [CrossRef]
  20. Kumar, M.R.; Park, A.; Park, N.; Lee, S. Consecutive condensation, C–N and N–N bond formations: A copper-catalyzed one-pot three-component synthesis of 2 H-indazole. Org. Lett. 2011, 13, 3542–3545. [Google Scholar] [CrossRef]
  21. Alomari, M.; Taha, M.; Rahim, F.; SelvaraJ, M.; Iqbal, N.; Chigurupati, S.; Hussain, S.; Uddin, N.; Almandil, N.B.; Nawaz, M.; et al. Synthesis of indole-based-thiadiazole derivatives as a potent inhibitor of α-glucosidase enzyme along with in silico study. Bioorganic Chem. 2021, 108, 104638. [Google Scholar] [CrossRef] [PubMed]
  22. Taha, M.; Rahim, F.; Ullah, H.; Wadood, A.; Farooq, R.K.; Shah, S.A.A.; Nawaz, M.; Zakaria, Z.A. Synthesis, in vitro urease inhibitory potential and molecular docking study of benzofuran-based-thiazoldinone analogues. Sci. Rep. 2020, 10, 10673. [Google Scholar] [CrossRef] [PubMed]
  23. Liu, F.; Luo, X.Q.; Song, B.A.; Bhadury, P.S.; Yang, S.; Jin, L.H.; Xue, W.; Hu, D.Y. Synthesis and antifungal activity of novel sulfoxide derivatives containing trimethoxyphenyl substituted 1, 3, 4-thiadiazole and 1, 3, 4-oxadiazole moiety. Bioorganic Med. Chem. 2008, 16, 3632–3640. [Google Scholar] [CrossRef] [PubMed]
  24. Yusuf, M.; Khan, R.A.; Ahmed, B. Syntheses and anti-depressant activity of 5-amino-1, 3, 4-thiadiazole-2-thiol imines and thiobenzyl derivatives. Bioorganic Med. Chem. 2008, 16, 8029–8034. [Google Scholar] [CrossRef] [PubMed]
  25. Taha, M.; Uddin, I.; Gollapalli, M.; Almandil, N.B.; Rahim, F.; Farooq, R.K.; Nawaz, M.; Ibrahim, M.; Alqahtani, M.A.; Bamarouf, Y.A.; et al. Synthesis, anti-leishmanial and molecular docking study of bis-indole derivatives. BMC Chem. 2019, 13, 102. [Google Scholar] [CrossRef] [PubMed]
  26. Taha, M.; Uddin, N.; Ali, M.; Rahim, F.; Khan, G.; Farooq, R.K.; Gollapalli, M.; Iqbal, N.; Farooq, M.; Khan, K.M. Inhibition potential of phenyl linked benzimidazole-triazolothiadiazole modular hybrids against β-glucuronidase and their interactions thereof. Int. J. Biol. Macromol. 2020, 161, 355–363. [Google Scholar] [CrossRef] [PubMed]
  27. Taha, M.; Almandil, N.B.; Rashid, U.; Ali, M.; Ibrahim, M.; Gollapalli, M.; Mosaddik, A.; Khan, K.M. 2, 5-Disubstituted thiadiazoles as potent β-glucuronidase inhibitors; Synthesis, in vitro and in silico studies. Bioorganic Chem. 2019, 91, 103126. [Google Scholar] [CrossRef]
  28. Alomari, M.; Taha, M.; Imran, S.; Jamil, W.; Selvaraj, M.; Uddin, N.; Rahim, F. Design, synthesis, in vitro evaluation, molecular docking and ADME properties studies of hybrid bis-coumarin with thiadiazole as a new inhibitor of Urease. Bioorganic Chem. 2019, 92, 103235. [Google Scholar] [CrossRef]
  29. Cressier, D.; Prouillac, C.; Hernandez, P.; Amourette, C.; Diserbo, M.; Lion, C.; Rima, G. Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles. Bioorganic Med. Chem. 2009, 17, 5275–5284. [Google Scholar] [CrossRef]
  30. Khan, Y.; Rehman, W.; Hussain, R.; Khan, S.; Malik, A.; Khan, M.; Liaqat, A.; Rasheed, L.; Begum, F.; Fazil, S.; et al. New biologically potent benzimidazole-based-triazole derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors along with molecular docking study. J. Heterocycl. Chem. 2022, 59, 2225–2239. [Google Scholar] [CrossRef]
  31. Hussain, R.; Rehman, W.; Rahim, F.; Khan, S.; Alanazi, A.S.; Alanazi, M.M.; Rasheed, L.; Khan, Y.; Shah, S.A.A.; Taha, M. Synthesis, In Vitro Thymidine Phosphorylase Inhibitory Activity and Molecular Docking Study of Novel Pyridine-derived Bis-Oxadiazole Bearing Bis-Schiff Base Derivatives. Arab. J. Chem. 2023, 16, 104773. [Google Scholar] [CrossRef]
  32. Khan, S.; Ullah, H.; Hussain, R.; Khan, Y.; Khan, M.U.; Khan, M.; Sattar, A.; Khan, M.S. Synthesis, in Vitro Bio-evaluation, and Molecular Docking Study of Thiosemicarbazone-based Isatin/bis-Schiff base Hybrid Analogues as Effective Cholinesterase Inhibitors. J. Mol. Struct. 2023, 1284, 135351. [Google Scholar] [CrossRef]
  33. Khan, S.; Rehman, W.; Rahim, F.; Hussain, R.; Obaidullah, A.J.; Alotaibi, H.F.; Alanazi, M.M.; Khan, M.U.; Khan, Y. Bis-indole based triazine derivatives: Synthesis, characterization, in vitro β-glucuronidase anti-cancer and anti-bacterial evaluation along with in silico molecular docking and ADME analysis. Arab. J. Chem. 2023, 16, 104970. [Google Scholar] [CrossRef]
  34. Anwar, S.; Rehman, W.; Hussain, R.; Khan, S.; Alanazi, M.M.; Alsaif, N.A.; Khan, Y.; Iqbal, S.; Naz, A.; Hashmi, M.A. Investigation of Novel Benzoxazole-Oxadiazole Derivatives as Effective Anti-Alzheimer’s Agents: In Vitro and In Silico Approaches. Pharmaceuticals 2023, 16, 909. [Google Scholar] [CrossRef]
Figure 1. Chemical structure for the reported Alzheimer’s disease drugs.
Figure 1. Chemical structure for the reported Alzheimer’s disease drugs.
Pharmaceuticals 16 01667 g001
Scheme 1. Synthetic procedure and reaction condition for the synthesis of indazole-based thiadiazole-bearing thiazolidinone derivatives (117). (a) Thiosemicarbazide, POCl3, Reflux 4 h; (b) NH4NCS, EtOH/Et3N, Reflux 4 h; (c) Thioglycolic acid, EtOH/CH3COOH, Reflux 8 h; (d) Benzaldehyde, EtOH/Et3N, Reflux 5 h.
Scheme 1. Synthetic procedure and reaction condition for the synthesis of indazole-based thiadiazole-bearing thiazolidinone derivatives (117). (a) Thiosemicarbazide, POCl3, Reflux 4 h; (b) NH4NCS, EtOH/Et3N, Reflux 4 h; (c) Thioglycolic acid, EtOH/CH3COOH, Reflux 8 h; (d) Benzaldehyde, EtOH/Et3N, Reflux 5 h.
Pharmaceuticals 16 01667 sch001
Figure 2. Structure of the potent scaffolds of synthesized indazole-based thiadiazole-bearing thiazolidinone derivatives (9, 14, 1, 16, and 15).
Figure 2. Structure of the potent scaffolds of synthesized indazole-based thiadiazole-bearing thiazolidinone derivatives (9, 14, 1, 16, and 15).
Pharmaceuticals 16 01667 g002
Figure 3. Compound 1’s closest interactions with AChE inhibitor active site residues.
Figure 3. Compound 1’s closest interactions with AChE inhibitor active site residues.
Pharmaceuticals 16 01667 g003
Figure 4. Compound 1’s closest interactions with BuChE inhibitor active site residues.
Figure 4. Compound 1’s closest interactions with BuChE inhibitor active site residues.
Pharmaceuticals 16 01667 g004
Figure 5. Compound 9’s closest interactions with AChE inhibitor active site residues.
Figure 5. Compound 9’s closest interactions with AChE inhibitor active site residues.
Pharmaceuticals 16 01667 g005
Figure 6. Compound 9’s closest interactions with BuChE inhibitor active site residues.
Figure 6. Compound 9’s closest interactions with BuChE inhibitor active site residues.
Pharmaceuticals 16 01667 g006
Figure 7. Compound 14’s closest interactions with AChE inhibitor active site residues.
Figure 7. Compound 14’s closest interactions with AChE inhibitor active site residues.
Pharmaceuticals 16 01667 g007
Figure 8. Compound 14’s closest interactions with BuChE inhibitor active site residues.
Figure 8. Compound 14’s closest interactions with BuChE inhibitor active site residues.
Pharmaceuticals 16 01667 g008
Table 1. Representation of various substitutions on indazole-based thiadiazole-bearing thiazolidinone skeleton along with their respective AChE and BuChE potential (117).
Table 1. Representation of various substitutions on indazole-based thiadiazole-bearing thiazolidinone skeleton along with their respective AChE and BuChE potential (117).
S. No.RAChE
IC50 ± SEM (µM)
BuChE
IC50 ± SEM (µM)
1Pharmaceuticals 16 01667 i0011.10 ± 0.371.19 ± 0.42
2Pharmaceuticals 16 01667 i0023.11 ± 0.593.36 ± 0.28
3Pharmaceuticals 16 01667 i0038.26 ± 0.408.80 ± 0.13
4Pharmaceuticals 16 01667 i0048.60 ± 1.058.84 ± 0.98
5Pharmaceuticals 16 01667 i00510.43 ± 0.9810.62 ± 0.74
6Pharmaceuticals 16 01667 i00612.73 ± 0.3312.98 ± 0.15
7Pharmaceuticals 16 01667 i0071.40 ± 0.311.57 ± 0.28
8Pharmaceuticals 16 01667 i0081.22 ± 0.641.29 ± 0.41
9Pharmaceuticals 16 01667 i0090.86 ± 0.300.89 ± 0.12
10Pharmaceuticals 16 01667 i01024.68 ± 0.1225.03 ± 0.44
11Pharmaceuticals 16 01667 i01126.73 ± 0.8427.08 ± 0.19
12Pharmaceuticals 16 01667 i01225.12 ± 0.1826.20 ± 0.67
13Pharmaceuticals 16 01667 i013N.A.N.A.
14Pharmaceuticals 16 01667 i0140.92 ± 0.100.98 ± 0.48
15Pharmaceuticals 16 01667 i0151.24 ± 0.361.27 ± 0.40
16Pharmaceuticals 16 01667 i0161.20 ± 0.581.20 ± 0.47
17Pharmaceuticals 16 01667 i01722.30 ± 1.0020.46 ± 0.86
Standard drug Donepezil1.26 ± 0.18 µM1.35 ± 0.37 µM
Table 2. In silico inhibitory potential of AChE and BuChE of indazole-based thiadiazole-bearing thiazolidinone scaffolds (1, 9 and 14).
Table 2. In silico inhibitory potential of AChE and BuChE of indazole-based thiadiazole-bearing thiazolidinone scaffolds (1, 9 and 14).
Active AnalogDistance (A°)Type of InteractionReceptorDocking Score
Compound 1 AChE5.82Conventional H–BPHE-A-288−11.86
4.92Conventional H–BARG-A-289
5.59Pi–AnionASP-A-72
5.42Pi–Pi StackedPHE-A-330
5.10Carbon H–BHIS-A-440
4.46Pi–Pi StackedTRP-A-84
3.98Pi–Pi T-shapedTRP-A-84
7.17Pi–AnionGLU-A-199
5.43Conventional H–BGLU-A-199
5.58Pi–Pi T-shapedGLY-A-117
6.27Pi–Pi StackedGLY-A-117
4.53Pi–SulfurTYR-A-334
4.53Pi–Pi T-shapedTYR-A-334
7.49Pi–Pi T-shapedTYR-A-121
7.92Pi–Pi T-shapedTRP-A-279
Compound 1 BuChE6.30Pi–AnionASP-A-70−7.56
4.08Unfavorable D–DASN-A-68
4.44Pi–AlkylHIS-A-438
4.19Conventional H–BTHR-A-120
3.61Carbon H–BGLY-A-116
4.11Pi–Pi StackedTRP-A-82
5.38Pi–AlkylTRP-A-82
Compound 9 AChE4.89Conventional H–BASN-A-85−10.34
6.19Amide–Pi StackedTYR-A-121
4.18Unfavorable D–DASP-A-72
4.31Pi–AnionASP-A-72
3.98Pi–Pi StackedTYR-A-334
5.42Conventional H–BSER-A-286
5.39H–FGLU-A-199
5.58H–FGLU-A-199
4.11Carbon H–BHIS-A-440
5.20Pi–AlkylHIS-A-440
5.05H–FHIS-A-440
4.52Pi–AlkylTRP-A-84
4.45Pi–Pi StackedTRP-A-84
5.44Pi–Pi StackedGLY-A-117
5.89Pi–AlkylPHE-A-330
6.87Pi–Pi StackedPHE-A-330
Compound 9 BuChE3.91Unfavorable D–DGLY-A-117−12.88
3.34Carbon H–BGLY-A-117
6.20Pi–AnionGLU-A-276
5.35Pi–AlkylALA-A-277
4.01Unfavorable D–DASN-A-68
5.75AlkylTRP-A-430
5.23Conventional H–BTRP-A-430
6.20
5.86
Alkyl
Conventional H–B
TYR-A-440
TYR-A-440
5.04H–FGLY-A-78
5.56AlkylMET-A-437
4.78AlkylALA-A-328
5.17Pi–AlkylALA-A-328
5.36Conventional H–BTRP-A-82
5.73AlkylTRP-A-82
5.02Pi–Pi StackedTRP-A-82
5.51H–FHIS-A-438
5.19Conventional H–BHIS-A-438
4.56Conventional H–BSER-A-198
Compound 14 AChE7.70Pi–Pi StackedTRP-A-279−6.99
4.39Pi–Pi StackedTYR-A-334
4.29Pi–SulfurTYR-A-334
6.26Pi–Pi StackedGLY-A-117
5.44Pi–Pi StackedGLY-A-117
5.23Pi–Pi StackedPHE-A-330
4.83Pi–Pi StackedTRP-A-84
4.06Pi–Pi StackedTRP-A-84
7.14Pi–AnionGLU-A-199
4.17H–FSER-A-286
Compound 14 BuChE4.40Pi–Pi StackedTRP-A-82−6.12
4.09Pi–Pi StackedTRP-A-82
6.06Pi–CationHIS-A-438
4.41Conventional H–BHIS-A-438
3.63H–FGLU-A-276
4.86H–FGLN-A-119
4.21Conventional H–BSER-A-287
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Khan, Y.; Khan, S.; Hussain, R.; Rehman, W.; Maalik, A.; Gulshan, U.; Attwa, M.W.; Darwish, H.W.; Ghabbour, H.A.; Ali, N. Identification of Indazole-Based Thiadiazole-Bearing Thiazolidinone Hybrid Derivatives: Theoretical and Computational Approaches to Develop Promising Anti-Alzheimer’s Candidates. Pharmaceuticals 2023, 16, 1667. https://0-doi-org.brum.beds.ac.uk/10.3390/ph16121667

AMA Style

Khan Y, Khan S, Hussain R, Rehman W, Maalik A, Gulshan U, Attwa MW, Darwish HW, Ghabbour HA, Ali N. Identification of Indazole-Based Thiadiazole-Bearing Thiazolidinone Hybrid Derivatives: Theoretical and Computational Approaches to Develop Promising Anti-Alzheimer’s Candidates. Pharmaceuticals. 2023; 16(12):1667. https://0-doi-org.brum.beds.ac.uk/10.3390/ph16121667

Chicago/Turabian Style

Khan, Yousaf, Shoaib Khan, Rafaqat Hussain, Wajid Rehman, Aneela Maalik, Urooba Gulshan, Mohamed W. Attwa, Hany W. Darwish, Hazem A. Ghabbour, and Nawab Ali. 2023. "Identification of Indazole-Based Thiadiazole-Bearing Thiazolidinone Hybrid Derivatives: Theoretical and Computational Approaches to Develop Promising Anti-Alzheimer’s Candidates" Pharmaceuticals 16, no. 12: 1667. https://0-doi-org.brum.beds.ac.uk/10.3390/ph16121667

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop